U.S. flag

An official website of the United States government

NM_000059.4(BRCA2):c.5851_5854del (p.Ser1951fs) AND Hereditary cancer-predisposing syndrome

Germline classification:
Pathogenic (3 submissions)
Last evaluated:
Jun 13, 2023
Review status:
2 stars out of maximum of 4 stars
criteria provided, multiple submitters, no conflicts
Somatic classification
of clinical impact:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Somatic classification
of oncogenicity:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Record status:
current
Accession:
RCV000131116.19

Allele description [Variation Report for NM_000059.4(BRCA2):c.5851_5854del (p.Ser1951fs)]

NM_000059.4(BRCA2):c.5851_5854del (p.Ser1951fs)

Gene:
BRCA2:BRCA2 DNA repair associated [Gene - OMIM - HGNC]
Variant type:
Deletion
Cytogenetic location:
13q13.1
Genomic location:
Preferred name:
NM_000059.4(BRCA2):c.5851_5854del (p.Ser1951fs)
Other names:
6076del4
HGVS:
  • NC_000013.10:g.32914340_32914343del
  • NC_000013.11:g.32340206_32340209del
  • NG_012772.3:g.29727_29730del
  • NM_000059.4:c.5851_5854delMANE SELECT
  • NP_000050.3:p.Ser1951fs
  • LRG_293:g.29727_29730del
  • NC_000013.10:g.32914340_32914343del
  • NC_000013.10:g.32914343_32914346del
  • NC_000013.10:g.32914343_32914346del
  • NC_000013.10:g.32914343_32914346delAGTT
  • NM_000059.3:c.5851_5854delAGTT
  • U43746.1:n.6076_6079delGTTA
  • U43746.1:n.6079_6082delAGTT
  • p.S1951WFS*11
  • p.S1951WfsX11
  • p.Ser1951Trpfs*11
  • p.Ser1951fs
Nucleotide change:
6079del4
Links:
Breast Cancer Information Core (BIC) (BRCA2): 6076&base_change=del GTTA; Breast Cancer Information Core (BIC) (BRCA2): 6079&base_change=del AGTT; dbSNP: rs80359543
NCBI 1000 Genomes Browser:
rs80359543
Molecular consequence:
  • NM_000059.4:c.5851_5854del - frameshift variant - [Sequence Ontology: SO:0001589]
Observations:
1

Condition(s)

Name:
Hereditary cancer-predisposing syndrome
Synonyms:
Neoplastic Syndromes, Hereditary; Tumor predisposition; Cancer predisposition; See all synonyms [MedGen]
Identifiers:
MONDO: MONDO:0015356; MeSH: D009386; MedGen: C0027672

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

Assertion and evidence details

Submission AccessionSubmitterReview Status
(Assertion method)
Clinical Significance
(Last evaluated)
OriginMethodCitations
SCV000186046Ambry Genetics
criteria provided, single submitter

(Ambry General Variant Classification Scheme_2022)
Pathogenic
(Feb 9, 2022)
germlineclinical testing

PubMed (8)
[See all records that cite these PMIDs]

Citation Link,

SCV000688951Color Diagnostics, LLC DBA Color Health
criteria provided, single submitter

(ACMG Guidelines, 2015)
Pathogenic
(Jun 13, 2023)
germlineclinical testing

PubMed (16)
[See all records that cite these PMIDs]

SCV002536179Sema4, Sema4
criteria provided, single submitter

(Sema4 Curation Guidelines)
Pathogenic
(Dec 17, 2021)
germlinecuration

PubMed (7)
[See all records that cite these PMIDs]

Citation Link

Summary from all submissions

EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
not providedgermlineunknown1not providednot provided1not providedclinical testing, curation

Citations

PubMed

A BRCA2 founder mutation and seven novel deleterious BRCA mutations in southern Chinese women with breast and ovarian cancer.

Kwong A, Wong LP, Wong HN, Law FB, Ng EK, Tang YH, Chan WK, Ho LS, Kwan KH, Poon M, Wong TT, Leung FC, Chan SW, Ying MW, Ma ES, Ford JM.

Breast Cancer Res Treat. 2009 Oct;117(3):683-6. doi: 10.1007/s10549-009-0385-2. Epub 2009 Apr 8. No abstract available.

PubMed [citation]
PMID:
19353265

BRCA1 and BRCA2 germline mutation analysis among Indian women from south India: identification of four novel mutations and high-frequency occurrence of 185delAG mutation.

Vaidyanathan K, Lakhotia S, Ravishankar HM, Tabassum U, Mukherjee G, Somasundaram K.

J Biosci. 2009 Sep;34(3):415-22.

PubMed [citation]
PMID:
19805903
See all PubMed Citations (23)

Details of each submission

From Ambry Genetics, SCV000186046.7

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not provided1not providednot providedclinical testing PubMed (8)

Description

The c.5851_5854delAGTT pathogenic mutation, located in coding exon 10 of the BRCA2 gene, results from a deletion of 4 nucleotides at nucleotide positions 5851 to 5854, causing a translational frameshift with a predicted alternate stop codon (p.S1951Wfs*11). This alteration has been reported in multiple breast and/or ovarian cancer families across various ethnicities (Kwong A et al. Breast Cancer Res. Treat. 2009 Oct;117:683-6; Papi L et al. Breast Cancer Res. Treat. 2009 Oct;117:497-504; Vaidyanathan K et al. J. Biosci. 2009 Sep;34:415-22; Juwle A et al. Med. Oncol. 2012 Dec;29:3272-81; Dodova RI et al. BMC Cancer. 2015 Jul;15:523; Labidi-Galy SI et al. Clin. Cancer Res. 2018 Jan;24(2):326-333; Jakimovska M et al. Breast Cancer Res. Treat. 2018 Apr;168(3):745-753; Fanale D et al. Cancers (Basel), 2020 Aug;12:; Wessman S et al. Cancers (Basel), 2021 Oct;13:). Of note, this alteration is also designated as 6079_6082delAGTT and 6079delAGTT in published literature. This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). In addition to the clinical data presented in the literature, this alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation.

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknown1not providednot provided1not providednot providednot provided

From Color Diagnostics, LLC DBA Color Health, SCV000688951.4

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testing PubMed (16)

Description

This variant deletes 4 nucleotides in exon 11 of the BRCA2 gene, creating a frameshift and premature translation stop signal. This variant is expected to result in an absent or non-functional protein product. This variant has been reported in individuals affected with breast and ovarian cancer (PMID: 12955716, 18821011, 25186627, 26183948, 27153395, 27882536, 29487695, 29335924, 29470806, 30430080, 32438681, 32854451, 33471991, 34101484, 34680387, DOI: https://doi.org/10.1515/tjb-2019-0424, Leiden Open Variation Database DB-ID BRCA2_002145, Color internal data). This variant has not been identified in the general population by the Genome Aggregation Database (gnomAD). Loss of BRCA2 function is a known mechanism of disease (clinicalgenome.org). Based on the available evidence, this variant is classified as Pathogenic.

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

From Sema4, Sema4, SCV002536179.1

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedcuration PubMed (7)
#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

Last Updated: Apr 20, 2024